SCHEMBL3757773

SCHEMBL3757773

CCN(C(=O)C(=O)Nc1[c]cccc1)N1CCCC1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.33
ALDH1A1 P00352 2/20 0.32
KCNQ2 O43526 3/20 0.32
CYP1A2 P05177 2/20 0.32
CYP2D6 P10635 2/20 0.32
CYP2C9 P11712 2/20 0.32
HTT P42858 1/20 0.32
KCNQ3 O43525 1/20 0.32
CYP3A4 P08684 1/20 0.32
KCNE1 P15382 1/20 0.32
KCNQ1 P51787 1/20 0.32
KCNQ4 P56696 1/20 0.32
GAA P10253 3/20 0.32
CYP2C19 P33261 1/20 0.31
LMNA P02545 2/20 0.30
SMN1; SMN2 Q16637 2/20 0.30
KMT2A Q03164 2/20 0.30
RAB9A P51151 1/20 0.30
HPGD P15428 1/20 0.30
MEN1 O00255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3761623 0.77 LMNA (0.36) ALDH1A1KCNQ2CYP2C9CYP2C19LMNA
SCHEMBL1667191 0.72 ABCC1 (0.46) ALDH1A1GAALMNASMN1; SMN2KMT2A
SCHEMBL3765649 0.72 ATM (0.32) HTT
SCHEMBL3765882 0.69 TSHR (0.49) ALDH1A1GAASMN1; SMN2KMT2ARAB9A
SCHEMBL3760338 0.69 POLB (0.42) MAPTHTTGAALMNASMN1; SMN2
SCHEMBL3757771 0.69 ATM (0.37) MAPTALDH1A1CYP1A2HTTGAA
SCHEMBL3759129 0.68 TSHR (0.51) ALDH1A1GAASMN1; SMN2KMT2ARAB9A
SCHEMBL1325735 0.68 KMT2A (0.51) MAPTALDH1A1CYP1A2HTTCYP2C19
SCHEMBL6554139 0.67 ALDH1A1 (0.53) MAPTALDH1A1HTTCYP3A4GAA
SCHEMBL3769100 0.67 GPR35 (0.51) MAPTALDH1A1GAASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA MAPT 790/4885ALDH1A1 3061/4885KCNQ2 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.